Managing Geographic Atrophy in Australia in 2026
Available from: 4/05/2026 (AEST)
Available from above date on OA online institute: https://lms.optometry.org.au/course/view.php?id=1005
Provider: Mivision
Contact: Nikki Byrne, [E] nikki@mivision.com.au, [P] 02 8336 8616
Activity Outline
With the
recent approval in Australia of two drugs for the treatment of geographic
atrophy (GA) secondary to age-related macular degeneration (AMD), the
Australian clinical community can now actively manage – rather than simply
monitor – the disease in their patients. In this article, Professor Robyn
Guymer and Associate Professor Zhichao Wu discuss how clinicians can best
identify those patients who will benefit most from GA treatments.
Learning Objectives
- Optimise the certainty of the diagnosis of atrophy being secondary to age-related macular degeneration,
- Identify lesion characteristics that have been associated with a faster rate of geographic growth, and
- Understand the trial outcomes in terms of visual benefit and trial limitations.
Max CPD hours awarded: 1.25
Session Information
| Name |
|---|
| Managing Geographic Atrophy in Australia in 2026 |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 0.75 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 1.25 |